Briefing
Molecular residual disease interception in locoregionally advanced HPV-positive and HPV-negative HNSCC
Phase 2 trial whose registry primary outcome is ctDNA clearance with AZD2936 compared with observation in locoregionally advanced head and neck squamous cell carcinoma that remains MRD-positive after definitive treatment. ClinicalTrials.gov lists the study as recruiting.
- Design: Phase 2 · Recruiting